Introduction
============

Chronic obstructive pulmonary disease (COPD) is currently the third leading cause of death in the USA, and worldwide it is one of the most prevalent lung diseases causing significant morbidity and mortality.[@b1-copd-11-2435],[@b2-copd-11-2435] Some patients are prone to episodes of acute exacerbations of COPD (AECOPD) that are a frequent cause of medical visits and hospitalizations. AECOPD are a leading cause of morbidity and mortality in COPD, and there is evidence that frequent exacerbations might accelerate the natural course of COPD.[@b3-copd-11-2435]--[@b6-copd-11-2435] Currently, there is no validated diagnostic test or biomarker to identify patients at risk of or with an exacerbation. Therefore, a diagnosis of an AECOPD is based on clinical symptoms for which there are no single standardized definition.

Recent technological advances in mass spectrometry have led to the emerging field of metabolomics, the study of small molecules. These small molecules consist of metabolic substrates and products, such as lipids, sugars, peptides, and foreign compounds such as drugs and their metabolites. Metabolomic profiling complements genomics and proteomics offering a snapshot into the physiology of human disease. In this respect, metabolomics has the opportunity to give us insight into mechanisms of disease and has the potential to identify biomarkers of disease.

In this study, we profiled the plasma metabolome in participants from the NIH-sponsored COPD Clinical Research Network. The cases were participants hospitalized for an AECOPD who had plasma collected within 24 hours of hospitalization and 30 days into recovery. Controls consisted of COPD participants matched for age and lung function in the absence of an AECOPD. We were able to characterize metabolomic profiles that distinguish an AECOPD and the presence of tryptophan catabolism via indoleamine 2,3-dioxygenase (IDO) activation.

Methods
=======

Study population
----------------

Subjects ([Table 1](#t1-copd-11-2435){ref-type="table"}) were 33 individuals with COPD (defined as having forced expiratory volume in 1 second \[FEV~1~\] \<60% predicted, FEV~1~ to forced vital capacity ratio \<70%, and minimum 10 pack-years of smoking) hospitalized for an AECOPD in the NIH-sponsored LEUKO study.[@b7-copd-11-2435] Plasma was collected within 24 hours of hospitalization (day 0) and then again in 30 days post-AECOPD (day 30). Controls (n=65) consisted of individuals with stable COPD from the NIH-sponsored MACRO study[@b8-copd-11-2435] matched for age, sex, lung function, and pack-years of smoking. Participants in the MACRO study were considered high risk for exacerbation as they were either using continuous oxygen therapy or had received systemic glucocorticoid steroids, had gone to the emergency room or been hospitalized for an AECOPD within the previous year. Samples from controls were obtained at baseline, prior to randomization, and subjects had not been treated for AECOPD for at least 4 weeks at the time of the plasma collection. Two controls were matched to each case for age and lung function (FEV~1~) with the exception of one case with only one matched control identified. This study was approved by the University of Minnesota Institutional Review Board and met exempt status for patient consent.

Sample preparation
------------------

Both cases and controls had identical protocols for obtaining plasma. These were nonfasting samples drawn at the time of enrollment into the study. Briefly, blood was drawn into an ethylenediaminetetraacetic acid-containing tube, inverted 8--10 times, and then centrifuged. Following centrifugation, 1.0 mL of plasma was transferred to a microtube (Sarstedt \[Nümbrecht, Germany\], RNAse, and DNAse free) and immediately frozen to −70°C. The samples remained at −70°C until use and were not freeze--thawed. Plasma samples were processed using a high-performance liquid chromatography-grade cold methanol (Sigma-Aldrich Co, St Louis, MO, USA) extraction method. The extraction methanol solution was cooled to −80°C. A volume of 400 μL of cold solvent was added to 100 μL of plasma. The mixture was gently shaken for 30 seconds and incubated for 6--8 hours at −20°C, then centrifuged for 15 minutes at 13,000 rpm at 4°C (in a cold room) and the supernatant transferred to a new tube. The pellet was rinsed twice with the cold solvent and the aforementioned procedure was repeated. The resulting supernatants were pooled and dried with a SpeedVac and stored at −80°C until further processing. A volume of the starting ultra-performance liquid chromatography (UPLC) buffer was added to the dried samples after they were acidified with formic acid (5 μL of formic acid \[50% v/v\]), to which 95 μL of the UPLC starting buffer was added (5% acetonitrile, 94.9% water, and 0.1% formic acid). After the samples were reconstituted, the solutions were centrifuged, to pellet out insoluble material, for 5 minutes at 13,000 rpm (4°C), and the supernatants were transferred to a Waters (Waters, Milford, MA, USA) 300 μL polypropylene plastic vial. For selective reaction monitoring (SRM) analysis, 100 μL of sample was added to 3 μL 100 μm kynurenine D6 and 3 μL 1 mm tryphtophan ^13^C11 (Cambridge Isotope Laboratories, Inc., Tewksbury, MA, USA) prior to protein precipitation. Samples were vacuum-dried and diluted to 10^−3^ for tryptophan and 10^−2^ for kynurenine with load buffer.

UPLC-MS analysis
----------------

For UPLC-MS^e^ analysis, a Waters Acquity UPLC coupled to a Waters Synapt G2 HDMS quadrupole orthogonal acceleration time of flight mass spectrometer was used. A Waters Acquity BEH C18 2.1×100 mm column (1.7 μm diameter particles) at 35°C was used during the following 26 minutes gradient separation with A: Water containing 0.1% formic acid; B: high-performance liquid chromatography grade acetonitrile (Fisher Scientific, Pittsburg, PA, USA) containing 0.1% formic acid, at a flow rate of 0.4 mL/minute: 3% B, 0--3 minutes; 3% B--97% B, 3--18 minutes; 97% B, 18--21 minutes; 97% B--3% B, 21--23 minutes; 3% B 23--26 minutes. Simultaneous low- and high-collision energy (CE) mass spectra were collected in centroid mode over the range mass/charge (*m/z*) 100--1,200 every 0.1 second during the chromatographic separation. MS^e^ parameters in positive electrospray ionization mode were as follows: capillary, 0.30 kV; sampling cone, 35.0 V; extraction cone, 4.0 V; desolvation gas flow, 800 L/hour; source temperature, 100°C; desolvation temperature, 350°C; cone gas flow, 20 L/hour; trap CE, off (low CE collection), ramp 15--65 V (high CE collection); Lockspray configuration consisted of infusion of a 5 μg/mL solution of leucine-enkephalin (Waters); and acquisition of one mass spectrum (0.2 second scan, *m/z* 100--1,200) every 10 seconds. Three lockspray *m/z* measurements of protonated leucine-enkephalin were averaged and used to apply corrections to measured *m/z* values during the course of the analysis. The R software package RAMClustR was used for analyte alignment and feature detection.[@b9-copd-11-2435]

SRM analysis of tryptophan and kynurenine
-----------------------------------------

Samples (10 μL) for SRM analysis were subjected to injection using an Agilent autosampler with an analytical Acquity UPLC BEH C18, 1.7 μm, 2.1×50 mm column fit with an Acquity UPLC BEH shield RP18 precolumn connected to the Applied Biosystem 5500 iontrap fit with a turbo V electrospray source. The samples were subjected to a linear gradient of 2% acetonitrile, 0.1% formic acid to 98% acetonitrile 0.1% formic acid for 10 minutes at a column flow rate of 250 μL/minute. Transitions monitored are listed in [Table S1](#SD1-copd-11-2435){ref-type="supplementary-material"}, and these were established using the instrument optimization mode with direct injection of native and heavy tryptophan and kynurenin. The data were analyzed using MultiQuant™ (ABI Sciex, Framingham, MA, USA), which provided the peak area ratio of tryptophan/tryptophan ^13^C11 and kynurenine/kynurenine D6 for the transitions. A standard curve was constructed using concentration ratios of tryptophan/tryptophan ^13^C11 and kynurenine/kynurenine D6 (Cambridge Isotope Laboritories, Inc., Tewksbury, MA, USA) from picomole to nanomole in 10 μL. Samples were run in duplicate and concentrations were determined from the standard curve. The correlation across duplicates for tryptophan was 0.9839 and for kynurenine was 0.9589.

Statistics
----------

The processed data from the MS experiments were transformed by adding 1 to all data points and taking the logarithm as the marginal distributions of the feature data were positively skewed (1 was added as many zeroes were observed in the data). To test for differences between cases and controls, a mixed-effects model was used with random effects for cluster membership (a case plus its two matched controls formed a cluster) and fixed effects for case--control status. The *p*-values from the test of no group effect were then adjusted for multiple comparisons using the method of Storey, and a false discovery rate (FDR) of 0.05 was used to select features for further investigation.[@b10-copd-11-2435] To test for differences between day 0 and day 30 among the cases, a paired *t*-test was used and adjustments for multiple hypothesis testing were conducted in the same manner as the test for differences between cases and controls. For the analysis of the data arising from the SRM experiments, a single mixed-effects model was fit that allowed testing for differences between cases and controls and for changes from day 0 to day 30 for tryptophan and kynurenine and their ratio. No adjustment was made for multiple hypotheses testing after fitting these models. These models also included the effects of sex, age, pack-years of smoking, lung function, and medications (steroids and antibiotics) as fixed effects and case--control group and subject as random effects (with subject effects nested within the case--control group effects) for the SRM experiments.

Results
=======

Characteristics of study participants
-------------------------------------

We analyzed two longitudinal plasma samples from 33 individuals with a COPD exacerbation who were recruited as part of the LEUKO study. Each subject had a plasma sample obtained within the first 24 hours of being hospitalized for a COPD exacerbation and a follow-up plasma sample obtained 30 days later. Controls consisted of individuals at high risk of developing AECOPD, but were currently free from an exacerbation ([Table 1](#t1-copd-11-2435){ref-type="table"}). All subjects had at least a ten pack-year history of smoking, with 27% of cases and 24% of controls reporting active smoking at the time of enrollment. The FEV~1~ ranged in severity from moderate to very severe according to the GOLD classification (GOLD II--IV), with the average FEV~1~ in the GOLD class III. The majority of subjects were on long- and short-acting β-agonists. The main difference in medications was more steroid and antibiotic use in the day 0 group compared to both day 30 and controls.

Analyte profiles
----------------

We detected over 3,000 analyte signals in the plasma. An analyte refers to a discreet *m/z* and retention time on the mass spectrometer that correlates with a yet unknown metabolite. Currently, there is no accepted methodology to quantify analytes detected by mass spectrometry. For our study, relative abundance was measured as the sum of all peak intensities detected by the mass spectrometer that associated with the given analyte. Using a mixed-effect model to account for the pairing of multiple controls to cases, we identified 583 analytes at 10% FDR and 386 analytes at a 5% FDR that were significantly different between samples at day 0 (cases) and controls. Using a paired *t*-test, we detected 54 analytes at 10% FDR and 34 analytes at a 5% FDR that were significantly different between samples at day 0 and day 30. A search within the Metlin library identified that several of the analytes found were consistent with the medications zileuton and prednisolone. These medications were anticipated since zileuton was the interventional drug administered in the LEUKO trial and since treatment with steroids is a common practice in an AECOPD. No other medications were identified. These analytes were eliminated, leaving 31 and 379 analytes at 5% FDR in the two groups (day 0 vs day 30 and controls vs day 0), respectively ([Tables S2](#SD2-copd-11-2435){ref-type="supplementary-material"} and [S3](#SD3-copd-11-2435){ref-type="supplementary-material"}). We found considerable overlap in the analytes between the two groups as depicted in the Venn diagram ([Figure 1](#f1-copd-11-2435){ref-type="fig"}). Of the 23 analytes in common between the two groups, nine are consistent with small peptides consisting of 3--4 amino acids and three are consistent with lipids ([Table S2](#SD2-copd-11-2435){ref-type="supplementary-material"}). [Figure 2](#f2-copd-11-2435){ref-type="fig"} demonstrates 25 representative analytes that are differentially expressed comparing day 0 to day 30, plus values for their respective controls. This figure demonstrates that the pattern of analytes show a similar value comparing day 0 and controls.

Tryptophan catabolism
---------------------

One of the analytes differentially expressed in day 0 subjects compared to controls was consistent with the essential amino acid tryptophan (Trp, *m/z* 204.23 and 257.09 methoxytryptophan). Since tryptophan catabolism has been associated with both immune modulation and infection, we sought to quantify tryptophan and its major metabolite, kynurenine. To identify tryptophan and measure its concentration, we performed SRM. IDO is the main inducible and rate-limiting enzyme involved in tryptophan catabolism, with kynurenine as the main metabolite of the IDO pathway. IDO activity is expressed as a ratio of kynurenine to tryptophan (Kyn/Trp). Statistical models included controlling for the effects of sex, age, pack years, lung function, and medications (steroids and antibiotics). We found that tryptophan was lower at day 30 compared to day 0 and higher in controls than day 0, but this was not statistically significant after controlling for the potential confounders ([Figure 3](#f3-copd-11-2435){ref-type="fig"}). We did find that kynurenine levels were significantly lower at day 30 compared to day 0 (*P*=0.00292, [Figure 3](#f3-copd-11-2435){ref-type="fig"}). With respect to IDO activity as measured by the Kyn/Trp ratio, Kyn/Trp was higher at day 0 compared to day 30 (*P*=0.0352) and higher at day 0 than in controls (*P*=0.0338, [Figure 4](#f4-copd-11-2435){ref-type="fig"}).

Discussion
==========

Patients with COPD often experience exacerbations, and, currently, there is no biomarker that either predicts or identifies those with an exacerbation. In this study, we identified a plasma metabolomic biosignature in COPD patients with an acute exacerbation. The largest profile was seen in COPD patients with an AECOPD (day 0) compared to matched controls. A smaller biosignature was identified in day 0 compared to day 30, and many of these analytes overlapped with the larger profile. This smaller biosignature suggests that full recovery from the exacerbation may not yet exist by day 30. This is not a surprise since one in eleven COPD patients are readmitted within 30 days following hospitalization.[@b11-copd-11-2435] Therefore, full recovery following a severe exacerbation may take longer than 30 days. As expected among these analytes, zileuton and prednisolone were identified. Zileuton was the parent trial study drug, and patients are often immediately placed on prednisone upon admission for an AECOPD.

One of the analytes in the profile comparing day 0 to controls was consistent with tryptophan. We used SRM to accurately measure tryptophan and its main metabolite kynurenine. We found that tryptophan levels are reduced early in the course of an AECOPD (day 0) compared to "healthy" COPD patients. This decrease in tryptophan is consistent with an increased catabolism through the IDO pathway as demonstrated by an increase in Kyn/Trp. After 30 days of recovery from an AECOPD, tryptophan levels remained significantly lower compared to control subjects; however, IDO activity was no longer increased at that time. This suggests that tryptophan catabolism was decreasing by day 30, but was incomplete. In this study, longitudinal samples were limited to 30 days; therefore, we do not know whether tryptophan levels eventually normalized, similar to controls.

Tryptophan is an essential amino acid and its deficiency limits protein synthesis, resulting in cellular dysfunction and decreased proliferation. Teleologically, it is felt that tryptophan catabolism is beneficial during infection, where a decline in tryptophan levels inhibits bacterial proliferation. Recent studies have also implicated tryptophan catabolism through the IDO pathway as having antimicrobial effects. The list of pathogens sensitive to tryptophan catabolism via IDO includes respiratory pathogens common in AECOPD such as Streptococci.[@b12-copd-11-2435] A decrease in serum tryptophan levels has been reported in pulmonary infections and predicts prognosis in both tuberculosis and community-acquired pneumonia.[@b13-copd-11-2435],[@b14-copd-11-2435] Since AECOPD is often due to respiratory tract infections, it is a possibility that tryptophan catabolism in that setting is actually a biomarker for infection.

Tryptophan catabolism is also an important factor in the lung microenvironment that influences immune responses. Tryptophan catabolism occurs predominantly through the activation of the enzyme IDO,[@b15-copd-11-2435],[@b16-copd-11-2435] producing metabolites of the kynurenine pathway. Most of the effects of tryptophan catabolism come from accumulation of its active metabolites, such as kynurenine, rather than tryptophan depletion.[@b15-copd-11-2435],[@b16-copd-11-2435] The generation of kynurenine through IDO activation leads to immune tolerance and an anti-inflammatory effect through the proliferation of T~reg~ FoxP3 cells and suppression of Th17 cells.[@b16-copd-11-2435],[@b17-copd-11-2435] The immune tolerance effect of IDO activation has been implicated in lung cancer and HIV infection.[@b18-copd-11-2435]--[@b22-copd-11-2435] Thus, tryptophan depletion and IDO activation have both antimicrobial and anti-inflammatory effects.[@b12-copd-11-2435]

Although decreases in tryptophan and IDO activation have been reported in lung cancer and certain lung infections, little is known of its role in COPD. Perturbations in amino acids in both serum and exhaled breath have been described in COPD using mass spectrometry and NMR.[@b23-copd-11-2435],[@b24-copd-11-2435] Ubhi et al[@b24-copd-11-2435] measured amino acid metabolism using mass spectrometry in COPD patients from the ECLIPSE cohort and found tryptophan levels were decreased in the serum of COPD patients with emphysema.[@b24-copd-11-2435] However, they did not assess IDO activity. However, Maneechotesuwan et al[@b25-copd-11-2435] found IDO activity decreased in the sputum of COPD patients that correlated with severity of disease and a reversal between the IL-10 and IL-17A balance. This suggests that a decrease in IDO activity within sputum creates an environment supporting neutrophilic inflammation.[@b25-copd-11-2435] In our study, we found tryptophan levels to be decreased in the plasma of patients with an AECOPD consistent with an activation of IDO, as measured by kynurenine and tryptophan ratios. This increase in IDO activity was still present at day 30, but to a lesser extent. A decrease in tryptophan would have an antimicrobial effect that would be beneficial in AECOPD, along with an anti-inflammatory effect to mitigate airway injury. The role of tryptophan catabolism in COPD and possible link to lung cancer remains unknown.

Many of the analytes that were common between the two biosignatures were multiply charged and had a retention time consistent with peptides consisting of 2--4 amino acids. Peptides as biomarkers for lung disease is not a new concept -- over 30 years ago, Kucich et al[@b26-copd-11-2435] detected elevated levels of unspecified serum peptides in COPD patients as measured by immunoassays. Using metabolomic profiling, protein degradation products have been detected in the serum of COPD patients, particularly those with emphysema and cachexia.[@b27-copd-11-2435] We have reported peptides in bronchoalveolar lavage fluid in COPD, many consistent with elastase activity.[@b28-copd-11-2435] Further studies are necessary to determine if these would serve as a biomarker for AECOPD.

There are several limitations of this study. First, our longitudinal samples were limited to day 30 post-AECOPD. Therefore, we do not know whether tryptophan levels remained low or continued to increase relative to controls. To identify biomarkers of AECOPD, we matched controls for lung function who were also frequent exacerbators, but who had not experienced an exacerbation for at least 1 month. Therefore, we do not know whether frequent exacerbators had different tryptophan levels and catabolism relative to healthy controls or COPD patients who do not experience exacerbations. Therefore, the role of tryptophan catabolism in frequent or prolonged exacerbations warrants future investigation.

Conclusion
==========

Patients with an AECOPD have a unique plasma metabolomic signature at the initiation of their exacerbation. This signature includes an increase in the Kyn/Trp ratio consistent with an increase in IDO activity. The role of tryptophan catabolism during AECOPD warrants further investigation.

Supplementary materials
=======================

###### 

Transitions for tryptophan and kynurenine

  Metabolite           Q1 *m/z*   Q2 *m/z*
  -------------------- ---------- ----------
  Tryptophan           204.892    188
  Tryptophan           204.892    169.9
  Tryptophan           204.892    158.96
  Tryptophan           204.892    117.908
  Kynurenine           208.92     191.904
  Kynurenine           208.92     145.943
  Kynurenine           208.92     135.957
  Kynurenine           208.92     94.049
  Tryptophan ^13^C11   216        199
  Tryptophan ^13^C11   216        169
  Tryptophan ^13^C11   216        154
  Tryptophan ^13^C11   216        140.9
  Kynurenine D6        215        198
  Kynurenine D6        215        150.9
  Kynurenine D6        215        142
  Kynurenine D6        215        98.2

**Note:** Q1 and Q2, first and second mass analyzers.

**Abbreviation:** *m/z*, mass/charge.

###### 

Analytes differentially expressed comparing day 0 to day 30

  RT        *m/z*      Putative identification
  --------- ---------- -------------------------
  0.4092    192.0339   
  0.3653    227.1242   
  1.5818    229.1532   Peptide
  0.6904    229.1537   Peptide
  0.6979    251.1345   Peptide
  3.5796    285.6607   
  1.0920    293.0517   
  0.6929    319.1215   
  1.0963    343.0335   
  1.0904    395.0595   
  1.0927    401.0747   
  1.0978    411.0227   
  2.2749    416.2397   
  2.2383    436.2067   Peptide
  2.2804    438.2229   
  1.9731    440.2379   
  0.3585    448.668    
  1.6195    456.2284   Peptide
  2.2801    479.2485   Peptide
  6.5000    480.3403   Lipid
  6.4761    482.3572   Lipid
  6.5022    502.3207   Peptide
  6.4766    504.3396   
  5.2860    509.3309   
  1.0933    531.0327   
  13.1409   531.4049   
  2.2757    541.2188   Peptide
  13.1434   594.4145   Lipid
  6.4827    606.3066   Peptide
  1.6767    709.0683   
  13.1658   940.523    

**Abbreviations:** RT, retention time; *m/z*, mass/charge.

###### 

Analytes differentially expressed comparing day 0 to controls

  RT        *m/z*      Putative identification
  --------- ---------- -------------------------
  1.8662    163.1318   
  1.6614    171.0983   
  1.86      185.1138   
  1.5791    191.1498   
  0.4092    192.0339   
  0.3588    193.1538   
  0.4057    198.0943   
  3.0522    199.1797   
  0.3585    203.0523   
  0.5741    204.1223   
  9.8983    208.0385   
  1.6615    212.1249   
  2.5382    213.1435   
  0.3442    219.026    
  3.0513    221.1605   
  3.4716    223.0953   
  1.8588    226.1407   
  1.1927    229.1528   
  1.5818    229.1532   Peptide
  0.6904    229.1537   Peptide
  1.0901    230.0336   
  1.5848    240.1584   
  13.7318   243.968    
  0.3551    244.0788   
  3.0993    244.1537   
  3.4708    245.078    
  1.0961    246.0052   
  0.7777    246.0236   
  1.6071    246.1656   
  8.6263    247.1305   Peptide
  3.0976    249.1076   
  0.6979    251.1345   Peptide
  1.5881    251.1353   
  13.7623   251.3842   
  1.0976    253.0267   
  2.5361    254.1701   
  1.6966    255.1202   
  0.4398    256.0572   
  1.6824    257.0866   
  8.8146    259.6639   
  0.3524    263.0841   
  0.8497    267.0591   
  3.8807    269.1376   
  0.3485    271.0384   
  1.6376    274.0912   
  1.0971    276.0376   
  0.3572    276.9842   
  3.2302    281.1351   
  5.1828    283.152    
  6.6211    283.2227   
  3.475     286.1041   
  0.3485    287.0129   
  1.0906    287.0312   
  2.2739    289.1319   
  3.0952    290.1338   Peptide
  1.7269    292.0288   
  1.6814    292.0944   
  1.092     293.0517   
  2.0077    295.1871   
  1.6749    297.0732   
  5.7355    300.1562   Peptide
  6.6352    305.2672   
  1.0892    309.0231   
  2.2719    309.6462   
  1.0864    315.036    
  4.693     316.1872   Peptide
  1.6716    319.0568   
  0.6929    319.1215   
  1.6643    319.2067   
  3.2243    322.1631   
  6.6409    322.2928   
  7.4187    322.6846   
  6.6068    324.2496   
  6.6439    327.2493   
  0.3577    330.7515   
  7.4216    331.6843   
  0.3551    332.7515   
  1.0892    337.0185   
  4.1134    338.2654   Sphingosine
  0.6137    339.0849   
  1.0963    343.0335   
  3.5422    343.2918   
  0.3486    344.9705   
  7.4247    345.688    
  1.6143    346.0417   
  5.1858    346.1605   Peptide
  1.1105    346.9641   
  0.3591    349.1201   Peptide
  6.6633    349.2919   
  13.0941   352.2866   
  3.8858    354.127    Peptide
  0.3356    355.0009   
  7.9032    355.2823   
  2.269     357.2031   Lipid
  8.8104    357.2973   
  1.5944    363.05     
  3.5481    365.2758   
  6.6604    366.3192   
  1.72      367.9704   
  0.3604    371.1011   
  6.6651    371.2745   
  4.726     371.3242   
  13.1143   372.7997   
  1.0931    373.074    
  7.4528    376.3162   
  7.901     377.2642   
  8.8109    379.2798   
  1.6829    381.0287   
  0.3593    383.114    
  1.6636    387.1926   
  2.1815    389.1957   
  0.3536    390.7096   
  4.7366    393.3058   
  1.0904    395.0595   
  1.6779    395.0655   
  0.3563    399.0878   
  6.2208    400.34     
  1.0927    401.0747   
  1.9865    402.2247   
  0.3465    402.9335   
  2.0137    404.2393   
  1.09      405        
  0.3504    405.096    
  1.6048    410.0573   
  6.6635    410.3434   
  1.0978    411.0227   
  0.9505    411.1445   
  10.2998   411.2636   Peptide
  2.2901    413.1735   Peptide
  6.6685    415.2991   
  2.2749    416.2397   
  1.9486    418.2552   Peptide
  1.0939    420.9697   Myo-inositol
  0.4032    421.0134   
  13.056    422.1534   Peptide
  1.986     424.2069   Peptide
  2.0219    426.2226   Peptide
  3.3009    430.3147   
  3.8793    435.1404   Peptide
  2.2383    436.2067   Peptide
  1.9411    438.2215   
  2.2804    438.2229   
  7.9047    439.2336   Peptide
  1.9731    440.2379   Peptide
  0.3602    441.0728   
  8.8391    441.2505   
  0.361     443.07     Peptide
  1.6293    443.2068   Peptide
  7.9101    445.253    Peptide
  1.6022    446.0764   
  0.3583    446.6695   
  0.4907    447.1107   
  0.3585    448.668    
  1.6604    450.0504   
  0.352     451.1009   
  13.1007   451.3301   
  2.1912    454.2176   
  6.6619    454.3717   
  6.6553    455.4541   
  0.571     456.0049   
  1.6195    456.2284   Peptide
  6.67      459.3263   Peptide
  1.7063    459.9791   
  0.4394    463.0131   
  0.7459    463.0142   
  1.6884    463.0538   
  1.5937    464.0727   Peptide
  0.3345    464.9774   
  1.9822    465.2359   Peptide
  12.737    467.0998   
  3.473     467.1661   Peptide
  10.3003   467.3253   
  4.9923    468.3055   
  0.987     469.0545   
  13.1096   469.3385   
  1.7225    470.9654   
  1.6195    472.0268   
  1.0919    479.012    
  1.6744    479.1225   Peptide
  2.2801    479.2485   Peptide
  8.8117    482.2728   Peptide
  5.5895    482.3202   
  7.9175    485.1119   
  4.993     490.2884   Peptide
  6.1727    496.3386   Lipid
  6.6598    498.3931   
  0.3607    499.0317   
  0.3661    501.0279   
  5.5152    502.2903   Peptide
  6.5022    502.3207   Peptide
  6.6618    503.3524   
  5.588     504.3023   Peptide
  9.342     505.1728   Peptide
  7.906     507.2218   Peptide
  0.3502    509.0611   
  8.8148    509.2378   Peptide
  6.6027    510.3528   Lipid
  0.4088    511.1077   
  10.3056   512.3832   
  1.6796    514.1279   Peptide
  4.3737    514.3133   Peptide
  0.3597    515.0057   
  0.374     517.1219   
  6.1755    518.3203   Lipid
  0.3419    518.8442   
  5.7313    520.3393   
  10.2989   521.3353   Peptide
  6.4842    522.3544   Lipid
  6.6752    522.355    
  7.4224    524.37     Lipid
  1.9592    527.2105   Peptide
  10.3044   528.3798   Peptide
  5.902     530.3202   
  10.3126   530.3374   Peptide
  0.3349    530.8702   
  1.0933    531.0327   
  0.3529    532.9185   
  13.773    536.1627   
  10.7768   537.3705   
  0.3335    538.905    
  0.3693    539.1055   
  5.7297    539.3104   
  13.7723   541.1272   Peptide
  2.2757    541.2188   Peptide
  5.7333    542.3218   
  6.6533    542.4236   
  1.952     543.2365   Peptide
  2.2779    546.1989   Peptide
  7.4211    546.3526   Lipid
  6.6677    547.3805   
  0.4231    548.0531   
  9.2218    554.1747   Peptide
  0.3499    554.8997   
  1.6083    555.0536   
  0.37      555.0773   
  2.2743    557.1907   
  9.2188    559.1309   
  0.3603    560.9874   
  7.4221    562.328    Peptide
  13.6      563.393    
  2.2754    568.1795   Peptide
  5.5875    572.2921   Peptide
  1.5933    572.3243   
  5.7311    573.3019   Peptide
  1.6231    574.0328   
  1.6091    577.0354   
  7.4223    577.3347   Peptide
  13.1318   577.4431   
  1.6266    585.0671   
  2.606     585.2705   Peptide
  6.6434    586.4511   
  10.3024   590.4088   
  6.932     590.4251   
  6.6434    591.4084   
  6.4549    592.2653   Peptide
  1.6239    598.3267   
  6.8086    600.3238   Peptide
  1.6056    601.1917   
  1.7112    603.939    
  5.7322    604.2916   
  6.4827    606.3066   Peptide
  0.3469    607.0939   
  7.415     608.3224   Peptide
  5.392     611.2865   Peptide
  6.6809    612.3241   Peptide
  7.4196    614.3404   
  0.3622    619.0479   
  4.3825    620.3067   Peptide
  0.3506    626.9787   
  13.6773   627.453    
  2.2746    630.1508   
  6.6362    630.4782   
  0.5446    633.0673   
  10.5995   633.1485   
  3.4554    633.2536   Peptide
  0.3616    635.0202   
  13.6383   635.3657   
  6.6358    635.4317   
  10.725    637.4437   
  1.6034    639.0026   
  0.359     644.7984   
  7.4254    646.2822   
  1.6088    649.9961   
  0.3528    655.0219   
  5.7638    665.2701   Peptide
  0.3547    670.9943   
  1.7155    673.9541   
  6.6237    674.5011   
  7.4111    676.3079   
  0.3492    676.9997   
  12.0071   677.554    
  0.3161    678.6746   
  6.6254    679.4573   Lipid
  1.7114    679.9699   
  0.3429    688.7822   
  1.7173    689.9271   
  0.3507    692.97     
  0.3477    694.9721   
  13.6232   703.4517   Lipid
  13.1358   703.5737   
  1.6767    709.0683   
  11.7477   712.5443   
  7.4314    713.3025   
  9.9864    717.632    Lipid
  6.6167    718.5284   
  13.4943   722.551    Ceramide
  6.6094    723.4853   
  5.7355    725.4297   Lipid
  13.1381   725.5549   
  7.4214    729.4603   
  13.5057   729.5885   
  0.3477    734.953    
  1.6269    735.4944   Lipid
  11.4089   739.5345   
  13.8137   740.5197   Lipid
  10.8899   741.5508   
  1.9897    743.3704   
  7.4197    744.2956   
  13.493    751.567    Lipid
  13.1615   754.0566   
  10.4529   758.5868   
  0.5736    759.0603   
  7.7516    760.5809   Lipid
  13.0793   764.0389   
  13.1581   765.0463   
  6.5956    767.509    
  2.2768    771.4027   
  13.132    771.5631   
  0.3524    772.9186   
  12.8808   774.5722   
  12.293    778.5329   Lipid
  13.1639   782.5684   Lipid
  13.1358   793.5442   
  10.3346   794.5649   Lipid
  13.7571   796.561    
  7.4286    797.4589   
  1.599     798.3899   
  5.7361    798.9721   
  5.7311    801.9803   
  13.1657   804.5514   Lipid
  14.361    806.5633   Lipid
  12.9319   806.5706   Lipid/ceramide
  13.2426   810.6704   
  0.3509    810.8878   
  2.2829    812.4288   
  8.6836    820.4116   
  12.6246   820.5522   Lipid
  13.0707   827.5999   
  12.9375   828.5527   Lipid
  13.9946   830.568    Lipid
  6.1864    830.961    
  5.7348    835.9755   
  0.3123    836.6608   
  6.4852    839.497    
  1.7063    841.9379   
  7.4234    842.023    
  10.3171   847.4601   
  11.7131   856.5728   
  5.7373    866.9606   
  5.7347    869.9697   
  13.1642   872.5377   Lipid
  8.8102    876.5694   
  11.9      882.5886   
  13.0421   884.6029   
  12.9953   893.0155   
  12.9321   896.5377   
  5.7506    900.2364   
  5.7392    900.9573   
  7.4281    910.0114   
  13.1352   929.5189   Lipid
  11.7452   939.4679   
  13.1658   940.523    
  1.6171    954.6025   
  11.4692   955.5848   
  13.0992   963.574    
  3.5652    979.9296   

**Abbreviations:** *m/z*, mass/charge; RT, retention time.
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![Venn diagram that depicts the number of analytes overlapping between the two comparison groups.](copd-11-2435Fig1){#f1-copd-11-2435}

![Analyte expression.\
**Notes:** 25/34 of the analytes identified at 5% FDR that were differentially expressed comparing day 0 and day 30. Top number is retention time and bottom number is *m/z*. *X*-axis: C = control, d0 = day 0, d30 = day 30. *Y*-axis: peak intensity.\
**Abbreviations:** FDR, false discovery rate; *m/z*, mass/charge.](copd-11-2435Fig2){#f2-copd-11-2435}

![Tryptophan and kynurenine expression.\
**Notes:** No statistically significant differences in tryptophan levels. Kynurenine levels were significantly lower at day 0 compared to day 30 (*P*=0.00292).](copd-11-2435Fig3){#f3-copd-11-2435}

![IDO activity as depicted by Kyn/Trp ratio.\
**Notes:** Tryptophan and kynurenine levels were measured in plasma by SRM. Kyn/Trp values were significantly higher at day 0 compared to day 30 (*P*=0.0352) and higher at day 0 than in controls (*P*=0.0338).\
**Abbreviations:** IDO, indoleamine 2,3-dioxygenase; SRM, selective reaction monitoring; Kyn/Trp, kynurenine/tryptophan.](copd-11-2435Fig4){#f4-copd-11-2435}

###### 

Characteristics of case and control subjects

  Characteristics            Cases day 0 (N=33)   Cases day 30 (N=33)   Controls (N=65)      *P*-value
  -------------------------- -------------------- --------------------- -------------------- -----------
  Age, years                 62.03 (51--78)       --                    62.57 (50--81)       0.1
  Sex: male                  18 (57%)             --                    38 (58%)             1
  FEV~1~ percent predicted   31.18 (14.9--75.2)   --                    34.49 (14.3--72.5)   0.07
  Pack years                 47.92 (11--150)      --                    44.90 (14--144)      0.23
  Beta agonist               22 (0.67)            23 (0.7)              51 (0.78)            0.42
  Methacholine antagonist    15 (0.45)            7 (0.21)              21 (0.32)            0.11
  LABA                       22 (0.67)            24 (0.73)             48 (0.74)            0.77
  LAMA                       21 (0.64)            18 (0.55)             46 (0.71)            0.28
  ICS                        23 (0.7)             24 (0.73)             48 (0.74)            0.94
  Steroids                   13 (0.39)            3 (0.09)              0 (0)                \<0.01
  Antibiotic                 17 (0.52)            6 (0.18)              0 (0)                \<0.01

**Notes:** For continuous variables, the mean and the range are presented (the latter in parentheses) and for binary variables the count and the percent are provided (the latter in parentheses). The *P*-value tests the null hypothesis of no difference among the three groups and is obtained from a linear mixed-effects model for continuous variables and from a generalized linear mixed-effects model with logistic link for binary variables.

**Abbreviations:** LABA, long-acting beta-agonist; LAMA, long-acting methacholine antagonist; ICS, inhaled corticosteroid; FEV~1~, forced expiratory volume in 1 second.

[^1]: For the COPD Clinical Research Network
